Biologic drugs are medicines that come from living organisms, like genes and proteins. Biologics make up about 5% of U.S. prescriptions, but more than 50% of total prescription drug spending in the country. Biosimilar drugs are biologic drugs that are highly similar compared to their reference products, which are existing biologics. Biosimilars are not exact…
Pharmacy Forward Podcast, Episode 2 Welcome to Episode 2 of Pharmacy Forward: Medical Rebates 101, featuring Azim Bari, Chief Clinical Officer and Sam Warman, VP, Client Consulting. Join our host Lesley Pink as she and our guests dive into the world of medical rebates, exploring how medical rebates differ from pharmacy rebates and why they…
This year, the prescription drug landscape is shifting from a focus on rebates toward a more transparent view of net costs. For years, manufacturer rebates paid to pharmacy benefit managers (PBMs) have been key to drug pricing. These rebates were meant to lower overall spend but they sometimes hid the real costs paid by payers…
Direct-to-consumer (DTC) pricing for medications is making a splash. With DTC, drug manufacturers sell medications directly to patients instead of through a retail pharmacy or pharmacy benefit manager (PBM). This is a shift from the traditional pharmacy model. Some drugs, including those for weight management, now have a DTC model. Eli Lilly & Co. and…
The first biosimilar was approved in the U.S. in 2015. And now, just over 10 years later, the U.S. Food & Drug Administration (FDA) has approved an additional 81 biosimilars. In 2025 alone, the FDA approved 18 new biosimilars for a range of indications. However, only 73% of those approved biosimilars have been launched as of September 2025. Last year, the U.S. market size for biosimilars was estimated to be $22.59 billion….
A Look into the 2026 Drug Pricing Landscape Welcome to Episode 1 of Pharmacy Forward: Insights from Insiders from Gateway Health Partners. Episode 1 features Azim Bari, chief clinical officer, Rachel Schlukebier, chief pricing officer, and Scott Webb, senior vice president of sales, all from Gateway. Join our host Lesley Pink as she and our…
What’s ahead in the GLP-1 market in 2026 The obesity rate has been increasing over time in the U.S. From August 2021 to August 2023, about 40% of American adults were considered obese. A recent study shows that these rates will continue to rise for about 20 more years. Complications related to obesity include heart…
From IRA implementation to the impacts of AMP Cap and biosimilar adoption, here are five market trends Gateway Health Partners is keeping an eye on as we head into 2026 and how we’re helping clients stay ahead as the market continues to evolve.